Kintara Therapeutics (KTRA) Receives a Hold from Dawson James

In a report released on November 18, Jason Kolbert from Dawson James maintained a Hold rating on Kintara Therapeutics (KTRAResearch Report). The company’s shares closed last Friday at $4.01.

According to TipRanks, Kolbert is an analyst with an average return of -5.1% and a 33.42% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as BioCardia, Can-Fite BioPharma, and Daré Bioscience.

Kintara Therapeutics has an analyst consensus of Hold.

See the top stocks recommended by analysts >>

The company has a one-year high of $42.08 and a one-year low of $3.67. Currently, Kintara Therapeutics has an average volume of 56.84K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Read More on KTRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More